Name: VIGAB-STAT (A phase IIa feasibility trial of irreversible GABA-transaminase inhibition as adjunct treatment of status epilepticus after cardiac arrest)

Contact: Ralisa Pop (Lead CRC 561-506-4903) and Jessica Spana (Back-up CRC, 813-943-2302), Dr. Carolina Maciel (PI)

Enrolling hours: technically 24/7, still need to work out on call schedule.

Diagnosis: PASE/ CA

Inclusion:

1. 18 – 80 years of age
2. Non-traumatic CA (regardless of non-perfusing rhythm, etiology, or location of arrest) in whom the decision to treat unequivocal electrographic SE (as defined by the American Clinical Neurophysiology Society[69]: having generalized spike/sharp-wave discharges ≥ 3Hz or any evolving pattern reaching > 4Hz, lasting ≥ 10 minutes, or comprising > 50% of any hour of recording) has been made
3. Requiring anesthetic infusion for any reason
4. Have reliable arterial access for frequent blood sampling
5. Established enteral access within 48h of PASE onset

Exclusion:

1. Prior history of generalized epilepsy
2. History of gastrointestinal surgery within the last 21 days
3. Pregnant women
4. PASE onset preceding initiation of EEG monitoring